---
layout: post
title: "Prospective Grant of Exclusive Patent License: Novel Therapeutics for the Treatment of Neurodegenerative Disorders"
date: 2026-02-05 18:35:33 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-02772
original_published: 2023-02-09 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of Exclusive Patent License: Novel Therapeutics for the Treatment of Neurodegenerative Disorders

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** February 09, 2023 00:00 UTC
**Document Number:** 2023-02772

## Summary

The National Institute of Neurological Disorders and Stroke ("NINDS"), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to University College London Business, Ltd. ("UCLB"), incorporated in England and Wales under company registration number 02776963 whose registered office address is University College London, Gower Street, London WC1E 6BT, United Kingdom, for NINDS's rights to the patent applications listed in the Supplementary Information section of this notice. UCLB is the technology transfer company of the University College London ("UCL"), a non-profit research institution located in London, United Kingdom.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/02/09/2023-02772/prospective-grant-of-exclusive-patent-license-novel-therapeutics-for-the-treatment-of)
- API: https://www.federalregister.gov/api/v1/documents/2023-02772

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
